ArticleHealth science reports2026
Trends and Disparities for Cardiovascular-Related Deaths With Underlying Pulmonary Fibrosis: A Retrospective 1999-2020 Analysis of CDC WONDER Data.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and disparities in deaths involving atherosclerotic cardiovascular disease and stroke-related conditions among U.S. adults, 1999-2025.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with increasing recognition of cardiovascular disease (CVD) as a major contributor to mortality. National data on cardiovascular deaths among individuals with IPF remains limited, and the impact of various disparities is unclear. The purpose of this study was to examine trends in the United States mortality rate involving cardiovascular deaths and pre-existing pulmonary fibrosis. Methods: This was a retrospective cohort study conducted by gathering mortality data from the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) publicly available database between the years 1999 and 2020. Death certificate data was extrapolated in this database, from which the subset of pulmonary fibrosis patients (ICD-10 J84.1) were analyzed for cardiovascular-related deaths (I00-I99). Statistical analysis was then conducted via the Joinpoint regression software. Results: There were 47,814 cardiovascular-related deaths with underlying pulmonary fibrosis between 1999 and 2000. The overall age-adjusted mortality rate (AAMR) per 100,000 increased from 59.1 in 1999 to 134.5 in 2020 (Annual percent change [APC] = 3.37%, Conclusions: Cardiovascular deaths with underlying pulmonary fibrosis have consistently increased from 1999 to 2020, highlighting the urgent need for preventative techniques and the necessity for additional targeted public health interventions based on demographic disparities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.